Letter to the Editor
Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus
Alemtuzumab y síndrome poliglandular autoinmune con diabetes mellitus tipo 1
a Servicio de Neurología, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
b Grupo de Investigación Neurociencias Clínicas, Instituto de Investigaciones Sanitarias Galicia-Sur, SERGAS-UVIGO, Vigo, Pontevedra, Spain
c Servicio de Endocrinología y Nutrición, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
Read
1346
Timeswas read the article
252
Total PDF
1094
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 29 | 6 | 35 |
| 2025 11 | 98 | 41 | 139 |
| 2025 10 | 62 | 19 | 81 |
| 2025 9 | 64 | 20 | 84 |
| 2025 8 | 66 | 20 | 86 |
| 2025 7 | 87 | 13 | 100 |
| 2025 6 | 65 | 13 | 78 |
| 2025 5 | 68 | 6 | 74 |
| 2025 4 | 47 | 6 | 53 |
| 2025 3 | 63 | 10 | 73 |
| 2025 2 | 41 | 10 | 51 |
| 2025 1 | 58 | 7 | 65 |
| 2024 12 | 53 | 14 | 67 |
| 2024 11 | 62 | 7 | 69 |
| 2024 10 | 28 | 4 | 32 |
| 2024 9 | 31 | 3 | 34 |
| 2024 8 | 38 | 8 | 46 |
| 2024 7 | 25 | 9 | 34 |
| 2024 6 | 24 | 8 | 32 |
| 2024 5 | 23 | 2 | 25 |
| 2024 4 | 36 | 5 | 41 |
| 2024 3 | 21 | 13 | 34 |
| 2024 2 | 5 | 8 | 13 |
Show all
